Claims
- 1. An intermediate peptide selected from the following peptides:
- H-Ala-Arg-Ala-Arg-Leu-NH.sub.2 called Fragment A hGRF (40-44) or alaninamide;
- H-Gln-Glu-Arg-Gly-OH called Fragment B'.sub.1 hGRF (36-39);
- H-Glu-Ser-Asn-OH called Fragment B'.sub.2 hGRF (33-35);
- H-Ser-Arg-Gln-Gln-Gly-OH called Fragment C hGRF (28-32);
- H-Leu-Gln-Asp-Ile-Met-OH called Fragment D' hGRF (23-27);
- H-Arg-Lys-Leu-OH called Fragment E'.sub.1 hGRF (20-22);
- H-Gln-Leu-Ser-Ala called Fragment F.sub.1 hGRF (16-19);
- H-Tyr-Arg-Lys-Val-Leu-Gly-OH called Fragment G.sub.1 hGRF (10-15)
- H-Ile-Phe-Thr-Asn-Ser-OH called Fragment H.sub.1 hGRF (5-9); and
- H-Tyr-Ala-Asp-Ala-OH called Fragment I hGRF (1-4).
- 2. Intermediate peptides, wherein said peptides are one of the following:
- Boc-Gln-Glu(0Bzl)-Arg-Gly-OH
- X-Gln-Glu-Arg-Gly-OH
- Boc-Glu-(0Bzl)-Ser-Asn-OH
- X-Glu-Ser-Asn-OH
- Boc-Arg(MTS)-Lys(Z)-Leu-OCH.sub.3
- X-Arg(MTS)-Lys(Z)-Leu-NH-NH.sub.2
- X-Gln-Glu(0Bzl)-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH.sub.2
- X-Glu(0Bzl)-Ser-Asn-Gln-Glu(0Bzl)-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH.sub.2
- X-Ser-Arg-Gln-Gln-Gly-Glu(0Bzl)-Ser-Asn-Gln-Glu(0Bzl)-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH.sub.2
- X-Leu-Gln-Asp(0Bzl)-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu(0Bzl)-Ser-Asn-Gln-Glu(0Bzl)-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH.sub.2
- X-Arg(MTS)-Lys(Z)-Leu-Leu-Gln-Asp(0Bzl)-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu(0Bzl)-Ser-Asn-Gln-Glu(0Bzl)-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH.sub.2
- X-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys(Z)-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg(MTS)-Lys(Z)-Leu-Leu-Gln-Asp(0Bzl)-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu(0Bzl)-Ser-Asn-Gln-Glu(0Bzl)-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH.sub.2,
- in which X is H or Boc.
- 3. As novel product the protected hGRF of formula:
- Y-Tyr-Ala-Asp(0Bzl)-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys(Z)-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg(MTS)-Lys(Z)-Leu-Leu-Gln-Asp(0Bzl)-Ile-Met-Ser-Arg-Gln-Gln-Gly-Gly(0Bzl)-Ser-Asn-Gln-Glu(0Bzl)-Arg-Gly-Ala-Arg-Ala-Arg-Leu-N.sub.2,
- in which Y is H, Z or Boc.
- 4. An intermediate peptide which is the following peptide:
- H-Tyr-Ala-Asp-Ala-OH (peptide I).
- 5. An intermediate peptide which is the following peptide:
- H-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-OH (peptide J).
- 6. An intermediate peptide which is the following peptide:
- H-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-OH.
- 7. An intermediate peptide which is the following peptide:
- H-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-HN.sub.2 (peptide K1).
Priority Claims (1)
Number |
Date |
Country |
Kind |
84 10965 |
Jul 1984 |
FRX |
|
Parent Case Info
This is a division of application Ser. No. 752,799 filed July 8, 1985, U.S. Pat. No. 4,707,541.
Foreign Referenced Citations (4)
Number |
Date |
Country |
0105759 |
May 1984 |
EPX |
0107890 |
May 1984 |
EPX |
0117034 |
Aug 1984 |
EPX |
0122818 |
Oct 1984 |
EPX |
Non-Patent Literature Citations (4)
Entry |
Chemical Abstracts, vol. 101, 1984, p. 86, No. 144228g. |
Chemical Abstracts, vol. 101, 1984, p. 80, No. 104311X. |
Chemical and Pharmaceutical Bulletin, vol. 32, No. 2, 1984, pp. 520-529. |
Chem. Abstr., vol. 102, 167169y (1985). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
752799 |
Jul 1985 |
|